Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr.Reddy's Laboratories Ltd    DRREDDY   INE089A01023

News SummaryMost relevantAll newsSector newsTweets 

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

share with twitter share with LinkedIn share with facebook
share via e-mail
03/05/2013 | 10:15am CEST

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at [email protected]/ +91-40-66834297
Saunak Savla at [email protected]/ +91-40-49002135
Milan Kalawadia (USA) at [email protected]/ +1 908-203-4931

S Rajan at [email protected]/ +91-40-49002445

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
04/27 DR REDDY LABORATORIES : Announces the Launch of Ezetimibe and Simvastatin Tablet..
04/24 DR REDDY LABORATORIES : announces the launch of Progesterone Capsules in the U.S..
04/23 DR REDDY LABORATORIES : . Reddy’s Lab launches Progesterone capsules in th..
04/21 DR REDDY LABORATORIES : Announces the Launch of Progesterone Capsules in the U.S..
04/17 DR REDDY LABORATORIES : Lab rises over 3% after Srikakulam facility clears USFDA
04/14 Clopidogrel Industry 2017 Deep Market Research Report Analysis, Forecast and ..
04/14 Sun, torrent, drl & lupin clasa's top pharma picks
04/13 DR REDDY LABORATORIES : 135 million small bottles of pure seawater have left Rij..
04/06 DR REDDY LABORATORIES : USFDA audits Dr Reddys Srikakulam API plant
04/06 DR REDDY LABORATORIES : Usfda audits dr reddy's plant
More news
Sector news : Pharmaceuticals - NEC
09:15a REGENERON PHARMACEUTICALS : Genzyme, CHC lift Sanofi's first-quarter figures, up..
07:45aDJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
04/27DJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue -- Update
04/27DJASTRAZENECA : Correction to AstraZeneca Profit Drops on Decline in Blockbuster-D..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/25 Dr. Reddy's launches progesterone caps in U.S.
03/27 Dr. Reddy's to distribute Integra's Duragen in India
03/24 The Case For India
03/20 Swiss Generic Manufacturer Siegfried Increased Sales And EBITDA
02/22 Momenta Delay Means Race For Copaxone Generic Is On
Financials ( INR)
Sales 2017 143 380 M
EBIT 2017 17 250 M
Net income 2017 14 103 M
Debt 2017 9 600 M
Yield 2017 0,66%
P/E ratio 2017 30,84
P/E ratio 2018 20,73
EV / Sales 2017 3,07x
EV / Sales 2018 2,68x
Capitalization 430 357 M
More Financials
Duration : Period :
Dr.Reddy's Laboratories Lt Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Full-screen chart
Technical analysis trends DR.REDDY'S LABORA...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 42
Average target price 3 038  INR
Spread / Average Target 17%
Consensus details
EPS Revisions
More Estimates Revisions
Gunupati Venkateswara Prasad Co-Chairman, Chief Executive Officer & MD
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Abhijit Mukherjee Chief Operating Officer
Kalpana Jaisingh Morparia Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON7.40%335 446
ROCHE HOLDING LTD.10.83%225 921
NOVARTIS AG2.77%203 449
PFIZER INC.4.25%201 641
MERCK & CO., INC.6.30%171 565
More Results